Document Detail

Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?
MedLine Citation:
PMID:  23002368     Owner:  NLM     Status:  MEDLINE    
AIM: To assess whether gemcitabine-based combination therapy improves the prognosis of unresectable pancreatic cancer compared with gemcitabine treatment alone.
METHODS: A quantitative up-to-date meta-analysis was undertaken to investigate the efficacy of gemcitabine-based combination treatment compared with gemcitabine monotherapy in locally advanced or metastatic pancreatic cancer. Inclusion was limited to high-quality randomized clinical trials.
RESULTS: Twenty-six studies were included in the present analysis, with a total of 8808 patients recruited. The studies were divided into four subgroups based on the different kinds of cytotoxic agents, including platinum, fluoropyrimidine, camptothecin and targeted agents. Patients treated with gemcitabine monotherapy had significantly lower objective response rate [risk ratio (RR), 0.72; 95% confidence interval (CI): 0.63-0.83; P < 0.001], and lower 1-year overall survival (RR, 0.90; 95%CI: 0.82-0.99; P = 0.04). Gemcitabine monotherapy caused fewer complications, including fewer grade 3-4 toxicities: including vomiting (RR, 0.75; 95%CI: 0.62-0.89; P = 0.001), diarrhea (RR, 0.66; 95%CI: 0.49-0.89; P = 0.006), neutropenia (RR, 0.88; 95%CI: 0.72-1.06; P = 0.18), anemia (RR, 0.96; 95%CI: 0.82-1.12; P = 0.60), and thrombocytopenia (RR, 0.76; 95%CI: 0.60-0.97; P = 0.03) compared with gemcitabine combination therapies.
CONCLUSION: Gemcitabine combination therapy provides a modest improvement of survival, but is associated with more toxicity compared with gemcitabine monotherapy.
Chen Sun; Daniel Ansari; Roland Andersson; De-Quan Wu
Related Documents :
24083748 - Evaluation of quality of life in turkish patients with head and neck cancer.
17613328 - Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a...
6149668 - High-dose neuroleptics for acute brain failure after intensive chemotherapy for acute l...
1586708 - Immunosuppressive therapy of aplastic anemia: results of a prospective, randomized tria...
15289018 - Addition of cyclosporin a to the combination of mitoxantrone and etoposide to overcome ...
7778218 - Solitary brain metastases from thyroid carcinoma: study of 6 cases.
Publication Detail:
Type:  Journal Article; Meta-Analysis; Review    
Journal Detail:
Title:  World journal of gastroenterology : WJG     Volume:  18     ISSN:  2219-2840     ISO Abbreviation:  World J. Gastroenterol.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-09-24     Completed Date:  2013-02-13     Revised Date:  2014-05-20    
Medline Journal Info:
Nlm Unique ID:  100883448     Medline TA:  World J Gastroenterol     Country:  China    
Other Details:
Languages:  eng     Pagination:  4944-58     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antimetabolites, Antineoplastic / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Chi-Square Distribution
Deoxycytidine / administration & dosage,  analogs & derivatives
Disease-Free Survival
Middle Aged
Odds Ratio
Pancreatic Neoplasms / drug therapy*,  mortality,  pathology
Survival Analysis
Time Factors
Treatment Outcome
Young Adult
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 0W860991D6/Deoxycytidine; B76N6SBZ8R/gemcitabine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Coexistence of hyperlipidemia and acute cerebral ischemia/reperfusion induces severe liver damage in...
Next Document:  Cameron ulcers: an atypical source for a massive upper gastrointestinal bleed.